Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.53 |
| ▸ | OGA | O60502 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944132 | 1.00 | P2RY12 (0.53) | P2RY12OGAHRH3PRMT1KMT2A | |
| SCHEMBL23630324 | 0.85 | SMO (0.45) | OGAHRH3KMT2AMEN1RAB9A | |
| SCHEMBL9210857 | 0.78 | P2RY12 (0.65) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL2820792 | 0.78 | P2RY12 (0.64) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL7529775 | 0.77 | P2RY12 (0.64) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL7469230 | 0.77 | P2RY12 (0.63) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL2428493 | 0.76 | P2RY12 (0.72) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL23630384 | 0.76 | PRMT1 (0.39) | P2RY12OGAPRMT1KMT2AMEN1 | |
| SCHEMBL3606423 | 0.76 | P2RY12 (0.59) | P2RY12OGAHRH3KMT2AMEN1 | |
| SCHEMBL29944247 | 0.76 | PRMT1 (0.39) | P2RY12OGAPRMT1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091042-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4087658-A1 | SMARCA2-VHL DEGRADERS | Amgen Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021142247-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021142247-A1 | SMARCA2-VHL DEGRADERS | AMGEN INC. (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091042-A1 | SMARCA2-VHL DEGRADERS | VHL, SMARCC2, SMARCC1 | P2RY12 4638/4885OGA 2487/4885HRH3 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.